{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:07Z","timestamp":1793295787936,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Based on good local control rates and an excellent safety profile, guidelines consider thermal ablation the gold standard to eliminate small unresectable colorectal liver metastases (CRLM). However, efficacy decreases exponentially with increasing tumour size. The preferred treatment for intermediate-size unresectable CRLM remains uncertain. This systematic review and meta-analysis compare safety and efficacy of local ablative treatments for unresectable intermediate-size CRLM (3\u20135\u00a0cm).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>We systematically searched for publications reporting treatment outcomes of unresectable intermediate-size CRLM treated with thermal ablation, irreversible electroporation (IRE) or stereotactic ablative body-radiotherapy (SABR). No comparative studies or randomized trials were found. Literature to assess effectiveness was limited and there was substantial heterogeneity in outcomes and study populations. Per-patient local control ranged 22\u201390% for all techniques; 22\u201389% (8 series) for thermal ablation, 44% (1 series) for IRE, and 67\u201390% (1 series) for SABR depending on radiation dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Focal ablative therapy is safe and can induce long-term disease control, even for intermediate-size CRLM. Although SABR and tumuor-bracketing techniques such as IRE are suggested to be less susceptible to size, evidence to support any claims of superiority of one technique over the other is unsubstantiated by the available evidence. Future prospective comparative studies should address local-tumour-progression-free-survival, local control rate, overall survival, adverse events, and quality-of-life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-022-01248-6","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:03:37Z","timestamp":1647497017000},"page":"793-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3\u20135\u00a0cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Sanne","family":"Nieuwenhuizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert S.","family":"Puijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Geboers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alette H.","family":"Ruarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J. J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M. E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester J.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Petrousjka","family":"van den Tol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. A.","family":"Haasbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn R.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"1248_CR1","unstructured":"WHO. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages 2018 [Available from: http:\/\/gco.iarc.fr\/today\/online-analysis-map Accessed 26\u201311\u20132018."},{"issue":"2","key":"1248_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","volume":"244","author":"S Manfredi","year":"2006","unstructured":"Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254\u20139.","journal-title":"Ann Surg"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/1471-2407-14-810","volume":"14","author":"C Hackl","year":"2014","unstructured":"Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.","journal-title":"BMC Cancer"},{"issue":"1","key":"1248_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","volume":"18","author":"J Engstrand","year":"2018","unstructured":"Engstrand J, Nilsson H, Stromberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78.","journal-title":"BMC Cancer"},{"issue":"22","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677\u201383.","journal-title":"J Clin Oncol"},{"issue":"8910","key":"1248_CR6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(94)92529-1","volume":"343","author":"R Stangl","year":"1994","unstructured":"Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343(8910):1405\u201310.","journal-title":"Lancet"},{"issue":"11","key":"1248_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/bjs.1800771115","volume":"77","author":"J Scheele","year":"1990","unstructured":"Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241\u20136.","journal-title":"Br J Surg"},{"issue":"5","key":"1248_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00000658-198405000-00002","volume":"199","author":"JS Wagner","year":"1984","unstructured":"Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer A comparison with resective treatment. Ann Surg. 1984;199(5):502\u20138.","journal-title":"Ann Surg"},{"key":"1248_CR9","doi-asserted-by":"crossref","unstructured":"House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010; 210(5):744-52, 52-5.","DOI":"10.1016\/j.jamcollsurg.2009.12.040"},{"key":"1248_CR10","first-page":"283","volume":"4","author":"GP Kanas","year":"2012","unstructured":"Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283\u2013301.","journal-title":"Clin Epidemiol"},{"issue":"12","key":"1248_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208\u201315.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1248_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.hpb.2020.10.003","volume":"23","author":"AKE Elfrink","year":"2021","unstructured":"Elfrink AKE, Nieuwenhuizen S, van den Tol MP, Burgmans MC, Prevoo W, Coolsen MME, et al. Hospital variation in combined liver resection and thermal ablation for colorectal liver metastases and impact on short-term postoperative outcomes: a nationwide population-based study. HPB (Oxford). 2021;23(6):827\u201339.","journal-title":"HPB (Oxford)"},{"issue":"4","key":"1248_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10434-001-0347-3","volume":"8","author":"R Adam","year":"2001","unstructured":"Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8(4):347\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1248_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38\u201347.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1248_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejso.2015.01.032","volume":"41","author":"H Malik","year":"2015","unstructured":"Malik H, Khan AZ, Berry DP, Cameron IC, Pope I, Sherlock D, et al. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study. Eur J Surg Oncol. 2015;41(4):499\u2013505.","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"1248_CR16","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/annonc\/mds053","volume":"23","author":"T Ruers","year":"2012","unstructured":"Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619\u201326.","journal-title":"Ann Oncol"},{"issue":"8","key":"1248_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00270-018-1959-3","volume":"41","author":"MR Meijerink","year":"2018","unstructured":"Meijerink MR, Puijk RS, van Tilborg A, Henningsen KH, Fernandez LG, Neyt M, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(8):1189\u2013204.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1248_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1053\/j.tvir.2015.06.007","volume":"18","author":"HJ Scheffer","year":"2015","unstructured":"Scheffer HJ, Melenhorst MC, Echenique AM, Nielsen K, van Tilborg AA, van den Bos W, et al. Irreversible electroporation for colorectal liver metastases. Tech Vasc Interv Radiol. 2015;18(3):159\u201369.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"13","key":"1248_CR19","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1245\/s10434-014-3817-0","volume":"21","author":"C Correa-Gallego","year":"2014","unstructured":"Correa-Gallego C, Fong Y, Gonen M, D\u2019Angelica MI, Allen PJ, DeMatteo RP, et al. A retrospective comparison of microwave ablation vs radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1248_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/bjs.6895","volume":"97","author":"AE van der Pool","year":"2010","unstructured":"van der Pool AE, Mendez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377\u201382.","journal-title":"Br J Surg"},{"issue":"3","key":"1248_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/cancers13030378","volume":"13","author":"M Dijkstra","year":"2021","unstructured":"Dijkstra M, Nieuwenhuizen S, Puijk RS, Geboers B, Timmer FEF, Schouten EAC, et al. The role of neoadjuvant chemotherapy in repeat local treatment of recurrent colorectal liver metastases: a systematic review and meta-analysis. Cancers. 2021;13(3):378.","journal-title":"Cancers"},{"key":"1248_CR22","doi-asserted-by":"crossref","unstructured":"Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an amsterdam colorectal liver met registry (AmCORE) based study. Cancers. 2021; 13(11).","DOI":"10.3390\/cancers13112769"},{"key":"1248_CR23","doi-asserted-by":"crossref","unstructured":"Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation: results from the Amsterdam Colorectal Liver Met Registry (AmCORE). Biomedicines. 2021; 9(8).","DOI":"10.3390\/biomedicines9080962"},{"key":"1248_CR24","doi-asserted-by":"crossref","unstructured":"Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Repeat local treatment of recurrent colorectal liver metastases, the role of neoadjuvant chemotherapy: an Amsterdam Colorectal Liver Met Registry (AmCORE) based study. Cancers (Basel). 2021; 13(19).","DOI":"10.3390\/cancers13194997"},{"key":"1248_CR25","doi-asserted-by":"crossref","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017; 109(9).","DOI":"10.1093\/jnci\/djx015"},{"issue":"1","key":"1248_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-018-4716-8","volume":"18","author":"RS Puijk","year":"2018","unstructured":"Puijk RS, Ruarus AH, Vroomen L, van Tilborg A, Scheffer HJ, Nielsen K, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18(1):821.","journal-title":"BMC Cancer"},{"issue":"6","key":"1248_CR27","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00268-013-1997-6","volume":"37","author":"K Nielsen","year":"2013","unstructured":"Nielsen K, van Tilborg AA, Meijerink MR, Macintosh MO, Zonderhuis BM, de Lange ES, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340\u20137.","journal-title":"World J Surg"},{"issue":"10","key":"1248_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s00270-016-1413-3","volume":"39","author":"AA van Tilborg","year":"2016","unstructured":"van Tilborg AA, Scheffer HJ, de Jong MC, Vroomen LG, Nielsen K, van Kuijk C, et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol. 2016;39(10):1438\u201346.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"1248_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ejca.2013.12.008","volume":"50","author":"E Tanis","year":"2014","unstructured":"Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014;50(5):912\u20139.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1248_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1148\/radiol.2211001624","volume":"221","author":"L Solbiati","year":"2001","unstructured":"Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221(1):159\u201366.","journal-title":"Radiology"},{"issue":"10","key":"1248_CR31","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1245\/s10434-008-0043-7","volume":"15","author":"E Berber","year":"2008","unstructured":"Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757\u201364.","journal-title":"Ann Surg Oncol"},{"issue":"1002","key":"1248_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1259\/bjr\/78268814","volume":"84","author":"AA Van Tilborg","year":"2011","unstructured":"Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011;84(1002):556\u201365.","journal-title":"Br J Radiol"},{"issue":"4","key":"1248_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.amjsurg.2009.11.009","volume":"200","author":"A Ayav","year":"2010","unstructured":"Ayav A, Germain A, Marchal F, Tierris I, Laurent V, Bazin C, et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg. 2010;200(4):435\u20139.","journal-title":"Am J Surg"},{"issue":"1","key":"1248_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","volume":"13","author":"A Mahadevan","year":"2018","unstructured":"Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D\u2019Ambrosio D, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018;13(1):26.","journal-title":"Radiat Oncol"},{"issue":"3","key":"1248_CR35","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","volume":"141","author":"M Scorsetti","year":"2015","unstructured":"Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543\u201353.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"1248_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/hpb.12044","volume":"15","author":"B Berber","year":"2013","unstructured":"Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford). 2013;15(11):851\u20137.","journal-title":"HPB (Oxford)"},{"issue":"7","key":"1248_CR37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/02841860600897934","volume":"45","author":"A Mendez Romero","year":"2006","unstructured":"Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i\u2013ii study. Acta Oncol. 2006;45(7):831\u20137.","journal-title":"Acta Oncol"},{"issue":"4","key":"1248_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bpg.2016.06.003","volume":"30","author":"A Mendez Romero","year":"2016","unstructured":"Mendez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: from technological evolution to improved patient care. Best Pract Res Clin Gastroenterol. 2016;30(4):603\u201316.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1248_CR39","doi-asserted-by":"crossref","unstructured":"Geboers B, Ruarus AH, Nieuwenhuizen S, Puijk RS, Scheffer HJ, de Gruijl TD, et al. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Chin Clin Oncol. 2019.","DOI":"10.21037\/cco.2019.10.05"},{"issue":"1","key":"1248_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.carj.2017.10.005","volume":"69","author":"AH Ruarus","year":"2018","unstructured":"Ruarus AH, Vroomen L, Puijk RS, Scheffer HJ, Zonderhuis BM, Kazemier G, et al. Irreversible electroporation in hepatopancreaticobiliary tumours. Can Assoc Radiol J. 2018;69(1):38\u201350.","journal-title":"Can Assoc Radiol J"},{"issue":"10","key":"1248_CR41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1248_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1148\/radiol.2021203715","volume":"301","author":"RS Puijk","year":"2021","unstructured":"Puijk RS, Ahmed M, Adam A, Arai Y, Arellano R, de Baere T, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301(3):533\u201340.","journal-title":"Radiology"},{"issue":"4","key":"1248_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00330-011-2314-0","volume":"22","author":"R Bale","year":"2012","unstructured":"Bale R, Widmann G, Schullian P, Haidu M, Pall G, Klaus A, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol. 2012;22(4):930\u20137.","journal-title":"Eur Radiol"},{"issue":"4","key":"1248_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jso.23849","volume":"111","author":"OS Eng","year":"2015","unstructured":"Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015;111(4):410\u20133.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1248_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3393\/jksc.2011.27.4.202","volume":"27","author":"JH Gwak","year":"2011","unstructured":"Gwak JH, Oh BY, Lee RA, Chung SS, Kim KH. Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer. J Korean Soc Coloproctol. 2011;27(4):202\u201310.","journal-title":"J Korean Soc Coloproctol"},{"issue":"7","key":"1248_CR46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11604-012-0089-0","volume":"30","author":"A Hamada","year":"2012","unstructured":"Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30(7):567\u201374.","journal-title":"Jpn J Radiol"},{"issue":"1","key":"1248_CR47","first-page":"211","volume":"36","author":"BB Jiang","year":"2019","unstructured":"Jiang BB, Yan K, Zhang ZY, Yang W, Wu W, Yin SS, et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia. 2019;36(1):211\u20139.","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"1248_CR48","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/jso.23268","volume":"107","author":"TJ Kennedy","year":"2013","unstructured":"Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol. 2013;107(4):324\u20138.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1248_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4174\/jkss.2011.81.1.25","volume":"81","author":"KH Kim","year":"2011","unstructured":"Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81(1):25\u201334.","journal-title":"J Korean Surg Soc"},{"issue":"4","key":"1248_CR50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/02656736.2017.1278622","volume":"33","author":"M Liu","year":"2017","unstructured":"Liu M, Huang GL, Xu M, Pan FS, Lu MD, Zheng KG, et al. Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. Int J Hyperthermia. 2017;33(4):446\u201353.","journal-title":"Int J Hyperthermia"},{"issue":"7\u20138","key":"1248_CR51","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/ans.15080","volume":"89","author":"R Mao","year":"2019","unstructured":"Mao R, Zhao JJ, Bi XY, Zhang YF, Han Y, Li ZY, et al. Resectable recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy? ANZ J Surg. 2019;89(7\u20138):908\u201313.","journal-title":"ANZ J Surg"},{"issue":"1","key":"1248_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/02656736.2018.1528511","volume":"36","author":"S Qin","year":"2019","unstructured":"Qin S, Liu GJ, Huang M, Huang J, Luo Y, Wen Y, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. Int J Hyperthermia. 2019;36(1):36\u201343.","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"1248_CR53","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1148\/radiol.2015142489","volume":"278","author":"W Shady","year":"2016","unstructured":"Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes\u2013a 10-year experience at a single center. Radiology. 2016;278(2):601\u201311.","journal-title":"Radiology"},{"key":"1248_CR54","doi-asserted-by":"crossref","unstructured":"Shi Y, Wang Z, Chi J, Shi D, Wang T, Cui D, et al. Long-term results of percutaneous microwave ablation for colorectal liver metastases. HPB (Oxford). 2020.","DOI":"10.1016\/j.hpb.2020.04.007"},{"key":"1248_CR55","doi-asserted-by":"crossref","unstructured":"Takahashi H, Kahramangil B, Kose E, Berber E. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB (Oxford). 2018.","DOI":"10.1016\/j.hpb.2018.02.069"},{"issue":"3","key":"1248_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1457496914553147","volume":"104","author":"C Valls","year":"2015","unstructured":"Valls C, Ramos E, Leiva D, Ruiz S, Martinez L, Rafecas A. Safety and efficacy of ultrasound-guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy. Scand J Surg. 2015;104(3):169\u201375.","journal-title":"Scand J Surg"},{"issue":"7","key":"1248_CR57","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s11547-012-0803-3","volume":"117","author":"A Veltri","year":"2012","unstructured":"Veltri A, Guarnieri T, Gazzera C, Busso M, Solitro F, Fora G, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med. 2012;117(7):1139\u201351.","journal-title":"Radiol Med"},{"issue":"9","key":"1248_CR58","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.4251\/wjgo.v12.i9.1044","volume":"12","author":"CZ Wang","year":"2020","unstructured":"Wang CZ, Yan GX, Xin H, Liu ZY. Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases. World J Gastrointest Oncol. 2020;12(9):1044\u201355.","journal-title":"World J Gastrointest Oncol"},{"key":"1248_CR59","doi-asserted-by":"crossref","first-page":"153303382096366","DOI":"10.1177\/1533033820963662","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang GY, Xu LC, He XH, Huang HZ, Li GD, et al. Clinical outcomes and predictors in patients with unresectable colorectal cancer liver metastases following salvage percutaneous radiofrequency ablation: a single center preliminary experience. Technol Cancer Res Treat. 2020;19:1533033820963662.","journal-title":"Technol Cancer Res Treat"},{"issue":"5","key":"1248_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3109\/02656736.2016.1156169","volume":"32","author":"K Zhang","year":"2016","unstructured":"Zhang K, Yu J, Zhou F, Yu X, Li X, Wang J, et al. Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation. Int J Hyperthermia. 2016;32(5):531\u20138.","journal-title":"Int J Hyperthermia"},{"key":"1248_CR61","doi-asserted-by":"crossref","unstructured":"Erten O, Li P, Gokceimam M, Akbulut S, Berber E. Impact of ablation algorithm versus tumor-dependent parameters on local control after microwave ablation of malignant liver tumors. J Surg Oncol. 2020.","DOI":"10.1002\/jso.26237"},{"issue":"5","key":"1248_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3727\/096504016X14567549091260","volume":"23","author":"Y Fan","year":"2016","unstructured":"Fan Y, Zhu X, Lan Q, Lou F, Zheng Y, Lou H, et al. Thermal radiofrequency ablation as an adjuvant therapy for patients with colorectal liver metastasis. Oncol Res. 2016;23(5):219\u201328.","journal-title":"Oncol Res"},{"issue":"1","key":"1248_CR63","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3892\/ol.2017.6167","volume":"14","author":"H Doi","year":"2017","unstructured":"Doi H, Uemoto K, Suzuki O, Yamada K, Masai N, Tatsumi D, et al. Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett. 2017;14(1):453\u201360.","journal-title":"Oncol Lett"},{"issue":"4","key":"1248_CR64","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","volume":"99","author":"JH Joo","year":"2017","unstructured":"Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1248_CR65","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ejso.2016.12.004","volume":"43","author":"P Fruhling","year":"2017","unstructured":"Fruhling P, Nilsson A, Duraj F, Haglund U, Noren A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results. Eur J Surg Oncol. 2017;43(4):751\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"1248_CR66","doi-asserted-by":"crossref","unstructured":"Franzese C, Comito T, Clerici E, Di Brina L, Tomatis S, Navarria P, et al. Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. J Cancer Res Clin Oncol. 2018.","DOI":"10.1007\/s00432-018-2692-7"},{"key":"1248_CR67","doi-asserted-by":"crossref","unstructured":"Nieuwenhuizen S, Dijkstra M, Puijk RS, Timmer FEF, Nota IM, Opperman J, et al. Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam CORE registry. Cancers. 2021; 13(17).","DOI":"10.3390\/cancers13174303"},{"key":"1248_CR68","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1186\/s12885-015-1736-5","volume":"15","author":"HJ Scheffer","year":"2015","unstructured":"Scheffer HJ, Vroomen LG, Nielsen K, van Tilborg AA, Comans EF, van Kuijk C, et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation\u2013a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer. 2015;15:772.","journal-title":"BMC Cancer"},{"key":"1248_CR69","unstructured":"ECIO. Ablation of colorectal liver metastases by irreversible electroporation: final results of the COLDFIRE-2 trial page 152019 [Available from: https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ecio2019\/ECIO_2019_Abstracts_and_Author_Index.pdf. Accessed November 14, 2019."},{"key":"1248_CR70","unstructured":"Belgian health care knowledge center (K.C.E.) National Clinical Practice Guidelines of the College of Oncology: clinical practice guideline for colrectal cancer. 2006."},{"key":"1248_CR71","unstructured":"National Institute for Health and Care Excellence (N.I.C.E.) Radiofrequency ablation for colorectal liver metastases 2009 [Available from: https:\/\/www.nice.org.uk\/guidance\/IPG327. Accessed 04\u201312\u20132019."},{"key":"1248_CR72","unstructured":"National Institute for Health and Care Excellence (N.I.C.E.) Microwave ablation for treating liver metastases 2016 [Available from: https:\/\/www.nice.org.uk\/guidance\/IPG553. Accessed 04\u201312\u20132019."},{"key":"1248_CR73","unstructured":"National Institute for Health and Care Excellence (N.I.C.E.) Irreversible electroporation for treating liver metastases 2013 [Available from: https:\/\/www.nice.org.uk\/guidance\/IPG445. Accessed 04\u201312\u20132019."},{"issue":"8","key":"1248_CR74","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"issue":"1","key":"1248_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12094-018-02002-w","volume":"21","author":"MA Gomez-Espana","year":"2019","unstructured":"Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol. 2019;21(1):46\u201354.","journal-title":"Clin Transl Oncol"},{"key":"1248_CR76","unstructured":"Integraal Kankercentrum Nederland (I.K.N.L.) Guideline Colorectaal Carcinoom 2019 [Available from: https:\/\/www.oncoline.nl\/colorectaalcarcinoom. Accessed 04\u201312\u20132019."},{"key":"1248_CR77","unstructured":"Cancer Care Ontario (C.C.O.) The role of liver resection in colorectal cancer metastases 2012 [Available from: https:\/\/www.cancercareontario.ca\/en\/content\/liver-resection-colorectal-metastases. Accessed 04\u201312\u20132019."},{"issue":"3","key":"1248_CR78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.currproblcancer.2010.04.006","volume":"34","author":"J Herman","year":"2010","unstructured":"Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, et al. ACR Appropriateness criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer. 2010;34(3):201\u201310.","journal-title":"Curr Probl Cancer"},{"key":"1248_CR79","doi-asserted-by":"crossref","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019.","DOI":"10.1007\/s10147-019-01485-z"},{"key":"1248_CR80","unstructured":"Scottish Intercollegiate Guidelines Network (S.I.G.N.) Diagnosis and management of colorectal cancer 2016 [Available from: https:\/\/www.sign.ac.uk\/assets\/sign126.pdf. Accessed 04\u201312\u20132019."},{"issue":"10","key":"1248_CR81","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","volume":"51","author":"JM Phelip","year":"2019","unstructured":"Phelip JM, Tougeron D, Leonard D, Benhaim L, Desolneux G, Dupre A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357\u201363.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1248_CR82","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/hep.30406","volume":"70","author":"R Bale","year":"2019","unstructured":"Bale R, Schullian P, Eberle G, Putzer D, Zoller H, Schneeberger S, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers. Hepatology. 2019;70(3):840\u201350.","journal-title":"Hepatology"},{"issue":"3","key":"1248_CR83","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00270-011-0200-4","volume":"35","author":"G Widmann","year":"2012","unstructured":"Widmann G, Schullian P, Haidu M, Bale R. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Intervent Radiol. 2012;35(3):570\u201380.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1248_CR84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejrad.2009.12.009","volume":"79","author":"J Yu","year":"2011","unstructured":"Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol. 2011;79(1):124\u201330.","journal-title":"Eur J Radiol"},{"issue":"7","key":"1248_CR85","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jvir.2008.03.023","volume":"19","author":"NC Yu","year":"2008","unstructured":"Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol. 2008;19(7):1087\u201392.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1248_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","volume":"32","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2016;32(3):339\u201344.","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"1248_CR87","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MEG.0b013e32835cb566","volume":"25","author":"Y Liu","year":"2013","unstructured":"Liu Y, Li S, Wan X, Li Y, Li B, Zhang Y, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol. 2013;25(4):442\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1248_CR88","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.radonc.2018.10.024","volume":"133","author":"C Franzese","year":"2019","unstructured":"Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2019;133:220\u20136.","journal-title":"Radiother Oncol"},{"issue":"40","key":"1248_CR89","doi-asserted-by":"publisher","first-page":"e12601","DOI":"10.1097\/MD.0000000000012601","volume":"97","author":"X He","year":"2018","unstructured":"He X, Zhang P, Li Z, Bi F, Xu F, Wang X, et al. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: a single-center study. Medicine (Baltimore). 2018;97(40):e12601.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1248_CR90","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585\u201391.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1248_CR91","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","volume":"18","author":"N Andratschke","year":"2018","unstructured":"Andratschke N, Alheid H, Allgauer M, Becker G, Blanck O, Boda-Heggemann J, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283.","journal-title":"BMC Cancer"},{"key":"1248_CR92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/1471-2407-14-619","volume":"14","author":"T Comito","year":"2014","unstructured":"Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619.","journal-title":"BMC Cancer"},{"issue":"1","key":"1248_CR93","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","volume":"19","author":"RJ Klement","year":"2019","unstructured":"Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G, et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer. 2019;19(1):173.","journal-title":"BMC Cancer"},{"issue":"2","key":"1248_CR94","first-page":"133","volume":"4","author":"KW Merrell","year":"2016","unstructured":"Merrell KW, Johnson JE, Mou B, Barney BM, Nelson KE, Mayo CS, et al. Stereotactic body radiotherapy for primary and metastatic liver tumors - the Mayo Clinic experience. J Radiosurg SBRT. 2016;4(2):133\u201344.","journal-title":"J Radiosurg SBRT"},{"issue":"3","key":"1248_CR95","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1248_CR96","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95(5):1399\u2013404.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1248_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.rpor.2016.10.003","volume":"22","author":"A Mendez Romero","year":"2017","unstructured":"Mendez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, IJzermans JNM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22(2):126\u201331.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"5","key":"1248_CR98","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3109\/0284186X.2013.766362","volume":"52","author":"S Stintzing","year":"2013","unstructured":"Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971\u20137.","journal-title":"Acta Oncol"},{"issue":"4","key":"1248_CR99","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","volume":"100","author":"WC Jackson","year":"2018","unstructured":"Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1248_CR100","first-page":"317","volume":"3","author":"E Lahat","year":"2014","unstructured":"Lahat E, Eshkenazy R, Zendel A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr. 2014;3(5):317\u201323.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1248_CR101","doi-asserted-by":"crossref","unstructured":"Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018.","DOI":"10.1016\/j.radonc.2018.06.035"},{"issue":"9","key":"1248_CR102","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.diii.2017.07.007","volume":"98","author":"L Vroomen","year":"2017","unstructured":"Vroomen L, Petre EN, Cornelis FH, Solomon SB, Srimathveeravalli G. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: what are the differences? Diagn Interv Imaging. 2017;98(9):609\u201317.","journal-title":"Diagn Interv Imaging"},{"key":"1248_CR103","doi-asserted-by":"crossref","unstructured":"Nieuwenhuizen S, Puijk RS, van den Bemd B, Aldrighetti L, Arntz M, van den Boezem PB, et al. Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION trial group. Cancers (Basel). 2020; 12(7).","DOI":"10.3390\/cancers12071779"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01248-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T12:40:43Z","timestamp":1651236043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01248-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"6 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}